Existing GLP1R agonists come with boxed warnings of thyroid cancer and pancreatitis, based mainly on rodent studies, where the effects of GLP1R agonism have noted species differences (For example, weight loss in rodents is mainly due to increased energy expenditure, whereas in humans it occurs via less food intake [54] )
Conclusion Staying motivated during GLP-1 treatment hinges on setting clear, personal goals that adapt as you progress, tackling challenges like side effects or plateaus before they throw you off track, and building routines that fit your lifestyle
Endocrinology 146 , 23692375 (2005)
The dysesthesia finding is unusual in the incretin class
Retatrutide is a GLP-1/GIP/GCGR agonist that is currently under development
That means your GLP-1 hormone pathways stay on for much longer than normal